Top Markets
Coin of the day
Orexo AB (publ) Orexo AB (publ)

Orexo AB (publ)

ORXOF
株式のランク #24996
Orexo AB (publ) functions as a specialized pharmaceutical company, focusing on... Orexo AB (publ) functions as a specialized pharmaceutical company, focusing on the innovation, advancement, and marketing of both conventional medicines and digital therapeutic solutions. Its commercial reach extends across the United States, Europe, and the United Kingdom. The firm's existing line of pharmaceutical products includes Zubsolv tablets, which are prescribed for addressing opioid dependence; Abstral, used to manage acute breakthrough pain in cancer patients; and Edluar, formulated for the brief treatment of insomnia. Looking to its future offerings, Orexo is actively progressing several developmental candidates: OX124, an emergency medication for naloxone rescue; OX125, an intervention for nalmefene rescue; OX640, a potential treatment for allergic reactions; and OX338, a sublingual ketorolac tablet designed for moderate to severe pain relief. Furthermore, the company is engaged in the OX-MPI program, which aims to tackle microvascular diseases often linked with chronic inflammatory conditions. Beyond traditional drugs, Orexo provides a selection of digital health therapies, such as deprexis, a program tailored for treating mild to severe depression; vorvida, targeted at alcohol use disorder; and modia, a digital tool for managing opioid use disorder. Established in 1994, Orexo AB (publ) operates from its primary corporate offices located in Uppsala, Sweden.
株価
$1.55
最終同期: 2026-08-19
時価総額
$54.45M
変化(1日)
0.00%
変化(1年)
-23.27%
SE
取引 Orexo AB (publ) (ORXOF)

カテゴリー

Orexo AB (publ)(ORXOF)の収益
Aug 2026 時点の収益 TTM: 0
Orexo AB (publ) の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Orexo AB (publ) の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。